Notice of Contract Award - Orexo US, Inc.

Location:	New Jersey
Posted:	Sep 26, 2025
Due:	Sep 24, 2025
Agency:	HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Type of Government:	Federal
Category:	A - Research and development
Solicitation No:	BARDA-BAA-OrexoNotice
Publication URL:	To access bid details, please log in.

Active

Contract Opportunity

Notice ID

BARDA-BAA-OrexoNotice

Related Notice

Department/Ind. Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub-tier

OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Office

BARDA - ASPR / DAAPPO / BARDA DCMA

General Information

Contract Opportunity Type: Special Notice (Original)
Original Published Date: Sep 26, 2025 01:05 pm EDT
Original Response Date: Sep 24, 2025 05:00 pm EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Oct 09, 2025
Initiative:
- None

Classification

Original Set Aside: No Set aside used
Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Place of Performance:
Morristown , NJ 07960

USA

Description

Award Notice for Orexo US, Inc. (Contract 75A50125C00010). Clinical development of OX390 (atipamezole) as an α2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other α2 agonists that are increasingly found in combination with IMF.

Attachments/Links

Contact Information

Contracting Office Address

O’NEILL HOUSE OFFICE BUILDING
WASHINGTON , DC 20515
USA

Primary Point of Contact

Jonathan Gonzalez, Contracting Officer
Jonathan.Gonzalez@hhs.gov
Phone Number 2023817248

Secondary Point of Contact

Joann Kambaja, Contract Specialist
Joann.Kambaja@hhs.gov
Phone Number 202-913-5470

History

Sep 26, 2025 01:05 pm EDTSpecial Notice (Original)

Notice of Contract Award - Orexo US, Inc.

See also